By Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Aug. 29, 2024

What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist?

We talk about all that and more on this week’s episode of “The Readout LOUD.” STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson’s exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly’s pitch to consumers, and more.

advertisement

For more on Wosen’s interview with Jim Wilson, go here; for more on Tome Biosciences’ financial struggles, go here; for details about its layoffs, go here; to learn more about how Eli Lilly’s push from weight loss injections to vials could ease supply constraints, go here; and for analysis on the Zepbound pricing changes, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

, , ,
Submit a correction requestReprints

  1. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

  2. Elaine Chen

    National Biotech Reporter

    Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

  3. Adam Feuerstein

    Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.